Breast cancer risk among patients with Klinefelter syndrome.
OBJECTIVE
To evaluate male breast cancer (MBC) risk among patients with Klinefelter syndrome (KS) and relate this to possible biological explanations.


METHODS
A literature review was conducted to identify case series and epidemiologic studies that have evaluated MBC risk among patients with KS.


RESULTS
Case reports without expected values have often led to false impressions of risk. Problems include that a diagnosis of cancer can prompt a karyotypic evaluation and that many cases of KS are unrecognized, resulting in incomplete denominators. Few carefully conducted epidemiologic studies have been undertaken given that both KS and MBC are rare events. The largest study found 19.2- and 57.8-fold increases in incidence and mortality, respectively, with particularly high risks among 47,XXY mosaics. These risks were still approximately 70% lower than among females, contradicting case reports that patients with KS have breast cancer rates similar to females. Altered hormone levels (especially the ratio of oestrogens to androgens), administration of exogenous androgens, gynaecomastia and genetic factors have been offered as possible explanations for the high risks.


CONCLUSIONS
Additional well-designed epidemiologic studies are needed to clarify which patients with KS are at a high risk of developing MBC and to distinguish between possible predisposing factors, including altered endogenous hormones.
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. brinton@nih.gov
Louise A
LA
Brinton
D018567:Breast Neoplasms, Male / Q000453:epidemiology*; D006801:Humans; D007713:Klinefelter Syndrome / Q000453:epidemiology*; D008297:Male; D012306:Risk
Breast Cancer Res Treat. 2010 Jan;119(1):185-92
19330525
Osteoporos Int. 1993 Jan;3(1):3-7
8422513
Clin Oncol. 1983 Sep;9(3):257-61
6311473
Ann Hum Genet. 2001 Mar;65(Pt 2):177-88
11427177
Br Med J. 1965 Jan 23;1(5429):223-5
14228155
Cancer Res. 1970 Jun;30(6):1769-72
4318704
J Med Genet. 1971 Dec;8(4):460-1
4337761
J Clin Endocrinol Metab. 2005 Dec;90(12):6516-22
16204366
J Epidemiol Community Health. 1985 Dec;39(4):330-6
4086964
J Natl Cancer Inst. 2005 Aug 17;97(16):1204-10
16106025
Acta Pathol Microbiol Scand Suppl. 1975;Suppl 251:3-35
1138536
BJU Int. 2007 Jan;99(1):141-6
17092285
Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):735-41
8672990
Plast Reconstr Surg. 2000 Oct;106(5):1011-3
11039372
J Clin Endocrinol Metab. 2006 Apr;91(4):1254-60
16394093
Anticancer Res. 1997 Nov-Dec;17(6D):4293-7
9494523
JAMA. 1974 Aug 12;229(7):809-11
4367182
CA Cancer J Clin. 1987 Jul-Aug;37(4):246-51
3111653
Horm Res. 2008;69(6):317-26
18504390
Northwest Med. 1955 May;54(5):472-6
14370607
Radiol Technol. 2010 Mar-Apr;81(4):361M-378M
20207793
Epidemiol Rev. 1993;15(1):220-31
8405206
Breast Cancer Res Treat. 2006 Apr;96(3):263-5
16418796
Curr Opin Urol. 2008 Nov;18(6):621-7
18832949
Am J Epidemiol. 1967 Mar;85(2):183-99
6020792
Cancer Res. 1988 Mar 1;48(5):1326-30
3342411
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6
15668471
J Natl Cancer Inst. 2008 Oct 15;100(20):1477-81
18840816
Diabetes Care. 2006 Jul;29(7):1591-8
16801584